Bromocriptine: Problems with low-dose de novo therapy in Parkinson's disease

J. D. Grimes, M. R. Delgado

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Twenty Parkinson's disease patients, who had not yet received levodopa, were treated with low-dose bromocriptine. At a mean daily bromocriptine dose of 13.2 mg, 13 patients (65%) improved and had a 32% reduction in the combined score for tremor rigidity and bradykinesia. Adverse effects were frequent, and 25% of the patients were taken off the drug because of nausea or vomiting. After 30 months follow-up, only three patients continued on bromocriptine alone. Ten patients were eventually maintained on low-dose bromocriptine and levodopa-carbidopa, and a clear synergistic effect of bromocriptine in this drug combination was documented in eight patients. Low-dose bromocriptine does not replace levodopa as initial therapy for Parkinson's disease. The potential long-term benefit of the early use of combined low-dose levodopa-dopamine agonist therapy needs to be further studied.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalClinical Neuropharmacology
Issue number1
StatePublished - Jan 1 1985

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Bromocriptine: Problems with low-dose de novo therapy in Parkinson's disease'. Together they form a unique fingerprint.

Cite this